CARM
Price
$0.40
Change
-$0.05 (-11.11%)
Updated
Mar 10, 04:59 PM (EDT)
Capitalization
16.7M
EDIT
Price
$1.55
Change
-$0.17 (-9.88%)
Updated
Mar 10, 04:59 PM (EDT)
Capitalization
129.03M
50 days until earnings call
Ad is loading...

CARM vs EDIT

Header iconCARM vs EDIT Comparison
Open Charts CARM vs EDITBanner chart's image
Carisma Therapeutics
Price$0.40
Change-$0.05 (-11.11%)
Volume$905
Capitalization16.7M
Editas Medicine
Price$1.55
Change-$0.17 (-9.88%)
Volume$42.84K
Capitalization129.03M
CARM vs EDIT Comparison Chart
Loading...
CARM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CARM vs. EDIT commentary
Mar 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CARM is a Buy and EDIT is a Hold.

Ad is loading...
COMPARISON
Comparison
Mar 11, 2025
Stock price -- (CARM: $0.40 vs. EDIT: $1.76)
Brand notoriety: CARM and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CARM: 55% vs. EDIT: 64%
Market capitalization -- CARM: $16.7M vs. EDIT: $129.03M
CARM [@Biotechnology] is valued at $16.7M. EDIT’s [@Biotechnology] market capitalization is $129.03M. The market cap for tickers in the [@Biotechnology] industry ranges from $355.07B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CARM’s FA Score shows that 0 FA rating(s) are green whileEDIT’s FA Score has 1 green FA rating(s).

  • CARM’s FA Score: 0 green, 5 red.
  • EDIT’s FA Score: 1 green, 4 red.
According to our system of comparison, EDIT is a better buy in the long-term than CARM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CARM’s TA Score shows that 2 TA indicator(s) are bullish while EDIT’s TA Score has 5 bullish TA indicator(s).

  • CARM’s TA Score: 2 bullish, 4 bearish.
  • EDIT’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, EDIT is a better buy in the short-term than CARM.

Price Growth

CARM (@Biotechnology) experienced а -2.77% price change this week, while EDIT (@Biotechnology) price change was -5.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.83%. For the same industry, the average monthly price growth was -7.68%, and the average quarterly price growth was -7.34%.

Reported Earning Dates

CARM is expected to report earnings on May 15, 2023.

EDIT is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (+0.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EDIT($129M) has a higher market cap than CARM($16.7M). EDIT YTD gains are higher at: 38.583 vs. CARM (-4.465). CARM has higher annual earnings (EBITDA): -63.37M vs. EDIT (-222.63M). EDIT has more cash in the bank: 265M vs. CARM (26.9M). CARM has less debt than EDIT: CARM (3.32M) vs EDIT (38.5M). EDIT has higher revenues than CARM: EDIT (61.8M) vs CARM (20.3M).
CARMEDITCARM / EDIT
Capitalization16.7M129M13%
EBITDA-63.37M-222.63M28%
Gain YTD-4.46538.583-12%
P/E RatioN/AN/A-
Revenue20.3M61.8M33%
Total Cash26.9M265M10%
Total Debt3.32M38.5M9%
FUNDAMENTALS RATINGS
CARM vs EDIT: Fundamental Ratings
CARM
EDIT
OUTLOOK RATING
1..100
5686
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
20
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9461
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (20) in the Biotechnology industry is significantly better than the same rating for CARM (95) in the null industry. This means that EDIT’s stock grew significantly faster than CARM’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CARM (100) in the null industry. This means that EDIT’s stock grew similarly to CARM’s over the last 12 months.

EDIT's SMR Rating (100) in the Biotechnology industry is in the same range as CARM (100) in the null industry. This means that EDIT’s stock grew similarly to CARM’s over the last 12 months.

EDIT's Price Growth Rating (61) in the Biotechnology industry is somewhat better than the same rating for CARM (94) in the null industry. This means that EDIT’s stock grew somewhat faster than CARM’s over the last 12 months.

EDIT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CARM (100) in the null industry. This means that EDIT’s stock grew similarly to CARM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CARMEDIT
RSI
ODDS (%)
N/A
Bearish Trend 7 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 7 days ago
80%
Bullish Trend 7 days ago
79%
Momentum
ODDS (%)
Bearish Trend 7 days ago
90%
Bullish Trend 7 days ago
80%
MACD
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 7 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 7 days ago
88%
Bearish Trend 7 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 7 days ago
87%
Bullish Trend 7 days ago
80%
Advances
ODDS (%)
Bullish Trend 25 days ago
84%
Bullish Trend 21 days ago
77%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 7 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 7 days ago
85%
Aroon
ODDS (%)
N/A
Bearish Trend 7 days ago
87%
View a ticker or compare two or three
Ad is loading...
CARM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X87222.1950001156.515600
+1.34%
Bitcoin cryptocurrency
GME24.30-0.10
-0.41%
GameStop Corp
AAPL235.93-2.10
-0.88%
Apple
SPY576.86-6.91
-1.18%
SPDR® S&P 500® ETF Trust
TSLA272.04-12.61
-4.43%
Tesla

CARM and

Correlation & Price change

A.I.dvisor tells us that CARM and ADCT have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CARM and ADCT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CARM
1D Price
Change %
CARM100%
-0.07%
ADCT - CARM
32%
Poorly correlated
+12.58%
SLRN - CARM
32%
Poorly correlated
-7.06%
TRDA - CARM
32%
Poorly correlated
-3.00%
TECH - CARM
31%
Poorly correlated
-1.75%
CLRB - CARM
31%
Poorly correlated
+3.19%
More

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with ALLO. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
-0.56%
ALLO - EDIT
50%
Loosely correlated
+5.56%
CRSP - EDIT
49%
Loosely correlated
+2.74%
NTLA - EDIT
48%
Loosely correlated
-3.76%
FATE - EDIT
47%
Loosely correlated
-7.77%
PRME - EDIT
47%
Loosely correlated
-1.34%
More